Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
NCT05633914Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in breast cancer, sponsored by Hunan Cancer Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Feb 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05633914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633914.